Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
By Ram Z, Kim C-Y, Hottinger AF, Idbaih A, Nicholas G and Zhu J-J (2022) Front. Oncol. 12:902929. doi: 10.3389/fonc.2022.902929
Due to a production error, there was an error in the title. The corrected title appears above. The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: elderly patients, newly diagnosed glioblastoma, TTFields, Tumor Treating Fields, phase 3 clinical trial, efficacy and safety, quality-of-life, temozolomide
Citation: Frontiers Production Office (2022) Erratum: Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. Front. Oncol. 12:952053. doi: 10.3389/fonc.2022.952053
Received: 24 May 2022; Accepted: 24 May 2022;
Published: 07 June 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org